Ironwood Pharmaceuticals (IRWD) Competitors $1.08 +0.01 (+0.47%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. ABBV, RIGL, EBS, VSTM, LXRX, XOMA, CBIO, VNDA, CDXS, and AGENShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include AbbVie (ABBV), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), and Agenus (AGEN). These companies are all part of the "medical" sector. Ironwood Pharmaceuticals vs. Its Competitors AbbVie Rigel Pharmaceuticals Emergent Biosolutions Verastem Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals Codexis Agenus AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Which has better earnings & valuation, ABBV or IRWD? AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B6.45$4.28B$2.1097.98Ironwood Pharmaceuticals$351.41M0.50$880K-$0.05-21.50 Is ABBV or IRWD more profitable? AbbVie has a net margin of 6.45% compared to Ironwood Pharmaceuticals' net margin of -2.25%. AbbVie's return on equity of 699.66% beat Ironwood Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AbbVie6.45% 699.66% 13.64% Ironwood Pharmaceuticals -2.25%-2.46%2.19% Which has more volatility and risk, ABBV or IRWD? AbbVie has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Do analysts prefer ABBV or IRWD? AbbVie currently has a consensus price target of $214.95, indicating a potential upside of 4.46%. Ironwood Pharmaceuticals has a consensus price target of $4.94, indicating a potential upside of 359.53%. Given Ironwood Pharmaceuticals' higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 5 Strong Buy rating(s) 2.96Ironwood Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 Does the media prefer ABBV or IRWD? In the previous week, AbbVie had 87 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 102 mentions for AbbVie and 15 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.15 beat Ironwood Pharmaceuticals' score of 0.14 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 72 Very Positive mention(s) 9 Positive mention(s) 14 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders believe in ABBV or IRWD? 70.2% of AbbVie shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAbbVie beats Ironwood Pharmaceuticals on 15 of the 17 factors compared between the two stocks. Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$175.58M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-21.5022.0530.2925.74Price / Sales0.50742.42470.66115.79Price / Cash22.04184.4138.2159.48Price / Book-0.574.838.846.15Net Income$880K$31.61M$3.25B$265.06M7 Day Performance19.86%4.55%3.72%2.60%1 Month Performance56.48%5.69%5.86%2.83%1 Year Performance-75.84%12.71%30.23%25.58% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.5047 of 5 stars$1.08+0.5%$4.94+359.5%-75.3%$175.58M$351.41M-21.50220ABBVAbbVie4.7383 of 5 stars$198.46+0.2%$214.43+8.0%+6.1%$349.87B$56.33B94.5055,000Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionRIGLRigel Pharmaceuticals1.8658 of 5 stars$33.46+5.6%$38.20+14.2%+216.5%$568.61M$179.28M6.18160Gap DownHigh Trading VolumeEBSEmergent Biosolutions4.7262 of 5 stars$8.18-4.6%$14.33+75.3%+16.1%$457.22M$1.04B3.342,420News CoverageVSTMVerastem3.1589 of 5 stars$7.70+14.2%$13.50+75.3%+240.5%$414.82M$10K-2.3550High Trading VolumeLXRXLexicon Pharmaceuticals2.8545 of 5 stars$1.04-3.7%$3.23+210.1%-28.0%$392.47M$31.08M-3.15140XOMAXOMA Royalty4.4928 of 5 stars$27.23+2.8%$69.50+155.2%+20.8%$317.12M$28.49M-23.6810Earnings ReportAnalyst RevisionGap UpCBIOCrescent Biopharma3.98 of 5 stars$12.90+0.4%$25.50+97.7%N/A$251.21M$10K-0.3750News CoverageAnalyst RevisionVNDAVanda Pharmaceuticals4.5812 of 5 stars$4.19-0.2%$16.50+293.8%-13.5%$248.17M$198.77M-3.71290News CoverageAnalyst RevisionCDXSCodexis3.6687 of 5 stars$2.80+1.1%$11.00+292.9%+9.9%$229.48M$59.35M-2.83250News CoverageEarnings ReportGap UpAGENAgenus4.0407 of 5 stars$4.27-11.0%$16.33+282.5%-0.7%$131.60M$103.46M-0.49440News CoverageEarnings ReportAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies AbbVie Alternatives Rigel Pharmaceuticals Alternatives Emergent Biosolutions Alternatives Verastem Alternatives Lexicon Pharmaceuticals Alternatives XOMA Royalty Alternatives Crescent Biopharma Alternatives Vanda Pharmaceuticals Alternatives Codexis Alternatives Agenus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access